ArticleBMC biotechnology2026
Rational design and high-yield expression of SARS-CoV-2 nucleocapsid antigen for a sensitive and specific in-house ELISA.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a global pathogen with a high prevalence rate. Among diagnostic methods, serological assays have been effective for rapid screening and identifying a history of infection or vaccination. The nucleocapsid protein is the most conserved and immunogenic antigen of SARS-CoV-2, making it a key target for such tests. Although commercial kits are available for this purpose, a custom design with superior specificity, sensitivity, and accuracy can be both clinically and economically advantageous. In the present study, we designed a recombinant nucleocapsid protein (rNP) using a multi-parameter suite of bioinformatic approaches, including codon optimization, ribosomal binding site engineering, mRNA secondary structure analysis, and optimized expression of the final construct in an E. coli system. The purified rNP was then applied in an in-house ELISA to compare its overall diagnostic efficacy with that of a commercially available kit on a pool of 37 predetermined positive and 15 negative sera for SARS-CoV-2.
resultsResults showed that both assays were 100% specific, but the in-house design showed higher sensitivity (91.9% vs. 83.8%) and a greater area under the curve (0.94 vs. 0.84) compared to the commercial ELISA.
conclusionThis demonstrates that our optimized rNP production platform enables the development of a high-performance serological assay with superior diagnostic accuracy compared to a commercial alternative, providing a powerful and economical tool for surveillance and research in the post-pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.